BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27093340)

  • 21. Liver resection in multimodal concepts improves survival of metastatic melanoma: a single-centre case-matched control study.
    Hau HM; Tautenhahn HM; Schoenberg MB; Atanasov G; Wiltberger G; Morgül MH; Uhlmann D; Seitz AT; Simon JC; Schmelzle M; Bartels M
    Anticancer Res; 2014 Nov; 34(11):6633-9. PubMed ID: 25368268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active-specific immunotherapy for melanoma.
    Mitchell MS; Harel W; Kempf RA; Hu E; Kan-Mitchell J; Boswell WD; Dean G; Stevenson L
    J Clin Oncol; 1990 May; 8(5):856-69. PubMed ID: 2139701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.
    Aarntzen EH; Bol K; Schreibelt G; Jacobs JF; Lesterhuis WJ; Van Rossum MM; Adema GJ; Figdor CG; Punt CJ; De Vries IJ
    Cancer Res; 2012 Dec; 72(23):6102-10. PubMed ID: 23010076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases.
    Jansen Y; Kruse V; Corthals J; Schats K; van Dam PJ; Seremet T; Heirman C; Brochez L; Kockx M; Thielemans K; Neyns B
    Cancer Immunol Immunother; 2020 Dec; 69(12):2589-2598. PubMed ID: 32591862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.
    Jones RC; Kelley M; Gupta RK; Nizze JA; Yee R; Leopoldo Z; Qi K; Stern S; Morton DL
    Ann Surg Oncol; 1996 Sep; 3(5):437-45. PubMed ID: 8876885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer.
    Salazar-Onfray F; Pereda C; Reyes D; López MN
    Biol Res; 2013; 46(4):431-40. PubMed ID: 24510145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T).
    Javed A; Sato S; Sato T
    Future Oncol; 2016 Mar; 12(6):751-62. PubMed ID: 26837440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.
    Wilgenhof S; Corthals J; Heirman C; van Baren N; Lucas S; Kvistborg P; Thielemans K; Neyns B
    J Clin Oncol; 2016 Apr; 34(12):1330-8. PubMed ID: 26926680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
    Wilgenhof S; Van Nuffel AM; Corthals J; Heirman C; Tuyaerts S; Benteyn D; De Coninck A; Van Riet I; Verfaillie G; Vandeloo J; Bonehill A; Thielemans K; Neyns B
    J Immunother; 2011 Jun; 34(5):448-56. PubMed ID: 21577140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New aspects of immunotherapy of malignant melanoma].
    Enk A
    Praxis (Bern 1994); 2001 Mar; 90(10):403-6. PubMed ID: 11305186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cells in melanoma immunotherapy.
    Faries MB; Czerniecki BJ
    Curr Treat Options Oncol; 2005 May; 6(3):175-84. PubMed ID: 15869729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma.
    Geskin LJ; Damiano JJ; Patrone CC; Butterfield LH; Kirkwood JM; Falo LD
    Melanoma Res; 2018 Jun; 28(3):211-221. PubMed ID: 29543704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next generation of immunotherapy for melanoma.
    Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
    J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
    Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
    Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
    Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
    Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients.
    Tuettenberg A; Becker C; Huter E; Knop J; Enk AH; Jonuleit H
    Int J Cancer; 2006 May; 118(10):2617-27. PubMed ID: 16353138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy for the management of advanced melanoma: the next steps.
    Zikich D; Schachter J; Besser MJ
    Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Vaccinal cell therapy in melanoma].
    Quillien V; Lesimple T; Toujas L
    Bull Cancer; 2003; 90(8-9):722-33. PubMed ID: 14609762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.